Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty Drugsharvard pilgrim coverage change Prior Auth | OpenP…
    Ask Trek AI about this page
    Currentharvard pilgrim health carePolicy N/A

    MassHealth changes to coverage and prior authorization of anti-obesity and GLP-1/GIP medications

    Customize your policy alerts

    Sign up for all harvard pilgrim health care policy alerts

    Know when harvard pilgrim health care releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Notifies payers/providers that MassHealth will stop covering drugs used for obesity/overweight effective July 1, 2026, describes which agents are affected, exceptions for certain medically accepted indications, and prior authorization (PA) handling and timelines.

    Policy Summary
    Payerharvard pilgrim health care
    PolicyMassHealth changes to coverage and prior authorization of anti-obesity and GLP-1/GIP medications
    Policy CodePolicy N/A
    Change TypeCoverage restriction and PA process changes
    Effective DateJul 1, 2026
    Next Review DateN/A
    Key ActionResubmit prior authorizations as needed and attach required documentation for MACE, MASH, or OSA to maintain coverage beyond June 30, 2026.
    SourceLink
    POLICY UPDATE CHANGES

    MassHealth will no longer cover drugs used for the treatment of obesity or overweight effective July 1, 2026; listed agents will not be covered for weight loss.

    GLP-1/GIP agents will remain coverable beyond June 30, 2026 only for specified medically accepted indications (MACE risk reduction, MASH, moderate-severe OSA) with documentation and approved PA.

    PAs submitted between Feb 17, 2026 and June 30, 2026 for weight-loss indications will be reviewed but, if approved for obesity/overweight without documented comorbidities, will expire June 30, 2026.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    2026-07-01Effective date drugs for weight loss no longer covered
    2026-06-30End date for existing PAs submitted before Feb 17, 2026
    6Maximum PA approval length with documentation for MACE/MASH/OSA

    Which agents are covered and when

    Coverage for Anti-Obesity Agents

    Anti-obesity/weight-loss agents listed below will not be covered for weight loss beginning July 1, 2026. Exceptions exist for other medically accepted indications as specified.

    ALL of the following

    • Drug is used for the treatment of obesity or overweight

      MassHealth will no longer cover these indications for listed agents effective 7/1/2026

    Listed agents: See Table 1 for affected agents (e.g., benzphetamine; diethylpropion; liraglutide [Saxenda]; orlistat [Xenical]; phendimetrazine; phentermine [Lomaira, Adipex-P]; semaglutide [Wegovy]; tirzepatide [Zepbound])

    Exceptions — GLP-1/GIP agents covered for other medically accepted indications

    GLP-1 or GIP/GLP-1 medications will be covered beyond June 30, 2026 when ALL of the following apply:

    ALL of the following

    • Approved indications (any one qualifies)

      • Body Mass Index (BMI) > 27 kg/m2 AND established cardiovascular disease to reduce risk of major adverse cardiovascular events (MACE)
      • Metabolic dysfunction-associated steatohepatitis (MASH)

        Documentation of fibrosis stage required for extended approval

      • BMI > 30 kg/m2 AND moderate to severe obstructive sleep apnea (OSA)

        Apnea–hypopnea index (AHI) score required for extended approval

    • Prior authorization is approved and appropriate documentation is attached

      If documentation not attached, PA will be end-dated to June 30, 2026

    Thresholds and PA duration: BMI thresholds: > 27 kg/m2 for MACE indication; > 30 kg/m2 for OSA indication. PA approvals for MACE, MASH, or OSA may be granted for up to 6 months when required documentation is attached.

    Prior Authorization submission windows and expirations

    Rules governing PA submissions and expirations based on submission date and indication:

    ANY of the following

    • ALL of the following

      • PAs submitted before Feb 17, 2026

        These will be end-dated to June 30, 2026 regardless of indication; must be resubmitted to receive paid claims beyond July 1, 2026

    • ANY of the following

      • If indication = obesity or overweight without documented comorbidities

        Approved PAs will expire June 30, 2026

      • If indication = diabetes or prediabetes

        Approvals will expire June 30, 2026; for continued coverage beginning July 1, 2026 members should be switched to an antidiabetic GLP-1

    Pediatric review

    Special review requirement for members under 21 years of age:

    ALL of the following

    • All requests for members under 21 will be reviewed for medical necessity in accordance with EPSDT requirements

    Affected drugs and MassHealth management list

    Listed anti-obesity agents (by drug name)NDC/drug namesNot Covered
    benzphetamineAnti-Obesity Agent
    diethylpropionAnti-Obesity Agent
    diethylpropion extended-releaseAnti-Obesity Agent
    Saxenda (liraglutide)Anti-Obesity Agent
    Xenical (orlistat)Anti-Obesity Agent
    phendimetrazineAnti-Obesity Agent
    phendimetrazine extended-releaseAnti-Obesity Agent
    Lomaira (phentermine)Anti-Obesity Agent
    Adipex-P (phentermine)Anti-Obesity Agent
    Wegovy (semaglutide)Anti-Obesity Agent
    1–10 of 11
    1/2
    Antidiabetic GLP-1 and GIP/GLP-1 agents (MassHealth management list)NDC/drug namesCovered
    Ozempic (semaglutide injection)PD/POS, GLP-1 Agonist; managed
    Bydureon Bcise (exenatide XR)Non-Preferred (exenatide extended-release auto-injection)
    Trulicity (dulaglutide)PD/POS, GLP-1 Agonist; managed
    Exenatide (Byetta/exenatide)Non-Preferred
    Victoza (liraglutide)BP/POS, GLP-1 Agonist; managed
    Rybelsus (oral semaglutide)Non-Preferred (semaglutide tablet)
    Mounjaro (tirzepatide)PD/POS, GIP and GLP-1 Agonist; managed

    What providers must do

    Prior Authorization

    Resubmit prior authorizations or expect end-dating

    PAs submitted before February 17, 2026 will be end-dated to June 30, 2026 and must be resubmitted to receive paid claims for dates of service on or after July 1, 2026. PAs submitted between February 17 and June 30, 2026 will be processed by the submitted indication but may still expire on June 30, 2026 depending on indication and documentation provided.

    • All listed anti-obesity agents
    • Antidiabetic GLP-1 and GIP/GLP-1 agents
    Documentation Required

    Attach documentation for MACE, MASH, OSA

    For PAs seeking continued coverage beyond June 30, 2026 for MACE, MASH, or moderate–severe OSA, attach objective documentation certifying severity (for example, AHI score for OSA, fibrosis stage for MASH, or documentation of established cardiovascular disease for MACE). Without this documentation the PA will be end-dated to June 30, 2026.

    Clinical and administrative context

    MassHealth is updating coverage consistent with anticipated regulation 130 CMR 406.413(B). Effective July 1, 2026, MassHealth will no longer cover medications when they are used specifically for the treatment of obesity or overweight; the agents listed as anti‑obesity drugs (for example, benzphetamine; diethylpropion and its extended‑release form; Saxenda [liraglutide]; Xenical [orlistat]; phendimetrazine and its extended‑release form; Lomaira and Adipex‑P [phentermine]; Wegovy [semaglutide]; and Zepbound [tirzepatide]) will not be covered for weight loss use.

    GLP‑1 and GIP/GLP‑1 agents used for diabetes and other specified medically accepted indications will continue to be managed on the MassHealth Drug List. These antidiabetic GLP‑1 and GIP/GLP‑1 medications remain subject to prior authorization (PA) requirements and may have non‑preferred designations for certain products; members receiving GLP‑1/GIP agents for diabetes or other covered indications should follow the MassHealth Drug List and PA criteria for those therapies.

    Existing prior authorizations submitted before February 17, 2026, will be end‑dated to June 30, 2026 and must be resubmitted to obtain paid claims beyond July 1, 2026. PAs submitted between February 17, 2026 and June 30, 2026 will be processed based on the submitted indication but, if approved for obesity/overweight without documented qualifying comorbidities, will expire on June 30, 2026.

    GLP‑1/GIP agents will remain coverable beyond June 30, 2026 only when used for other medically accepted indications with an approved PA and required supporting documentation (examples: BMI > 27 kg/m2 with established cardiovascular disease for MACE risk reduction; MASH with documented fibrosis stage; or BMI > 30 kg/m2 with moderate–severe OSA documented by AHI). When documentation for MACE, MASH, or OSA is attached, PAs may be approved for up to six months; without that documentation, the PA will be end‑dated to June 30, 2026.

    Defined terms

    Definitions
    MACEMajor adverse cardiovascular events; GLP-1 coverage exception applies for BMI > 27 kg/m2 with established cardiovascular disease to reduce MACE risk.
    MASHMetabolic dysfunction-associated steatohepatitis; PA approvals require documentation of fibrosis stage for extended approval.
    OSAObstructive sleep apnea; coverage exception requires BMI > 30 kg/m2 and documentation of moderate to severe OSA (e.g., AHI score).
    EPSDTEarly and Periodic Screening, Diagnostic, and Treatment — all requests for members under 21 will be reviewed under EPSDT medical necessity requirements.

    Policy changes and important dates

    2026-07-01revisedLatest

    MassHealth will no longer cover drugs used for the treatment of obesity or overweight effective July 1, 2026; listed agents will not be covered for weight loss. Existing prior authorizations submitted before Feb 17, 2026 will be end-dated to June 30, 2026 and must be resubmitted for coverage beyond July 1, 2026.

    clarified

    PAs for MACE, MASH, or OSA will be reviewed and may be approved for up to six months if appropriate documentation is attached; if documentation is not attached, PAs for these indications will be end-dated to June 30, 2026.

    At-a-glance dates and thresholds

    Key dates, thresholds, and PA limits
    Effective date (no coverage for weight loss)July 1, 2026
    End date for existing PAs submitted before Feb 17, 2026June 30, 2026
    Maximum PA approval length for MACE, MASH, OSA with documentationUp to 6 months
    BMI threshold for MACE indication> 27 kg/m2
    BMI threshold for OSA indication> 30 kg/m2
    Policy Summary
    Payerharvard pilgrim health care
    PolicyMassHealth changes to coverage and prior authorization of anti-obesity and GLP-1/GIP medications
    Policy CodePolicy N/A
    Change TypeCoverage restriction and PA process changes
    Effective DateJul 1, 2026
    Next Review DateN/A
    Key ActionResubmit prior authorizations as needed and attach required documentation for MACE, MASH, or OSA to maintain coverage beyond June 30, 2026.
    SourceLink
    On This Page
    Which agents are covered and whenAffected drugs and MassHealth management listWhat providers must doClinical and administrative contextDefined termsPolicy changes and important datesAt-a-glance dates and thresholds
    If indication = MACE, MASH, or OSA with documentation attached

    PAs will be reviewed and may be approved for up to six months

    Operational note: Changes to PA criteria announced in Prescriber eLetter went into effect Feb 17, 2026; documentation (e.g., AHI for OSA, fibrosis stage for MASH) is required for extended approvals.
  1. Example documentation: apneahypopnea index (AHI) score for OSA; fibrosis stage for MASH; clinical documentation of established CVD for MACE
  2. Prior Authorization

    Diabetes/prediabetes approvals require switching for continued coverage

    Approvals for diabetes or prediabetes will expire on June 30, 2026; to ensure continued coverage beginning July 1, 2026, members should be switched to an antidiabetic GLP-1 that is listed on the MassHealth Drug List.

    • Antidiabetic GLP-1 and GIP/GLP-1 agents
    Denial Risk

    Risk of end-dating/denial if documentation missing

    If the required objective documentation certifying severity for MACE, MASH, or OSA is not attached to the PA, the PA will be end-dated to June 30, 2026, creating risk of denial for coverage beyond that date.

    • Attach supporting objective tests (e.g., AHI for OSA, fibrosis stage for MASH, documentation of established CVD) to avoid end-dating.
    clarified

    Approvable PAs for diabetes or prediabetes will expire on June 30, 2026; for continued coverage beginning July 1, 2026, members should be switched to an antidiabetic GLP-1 available on the MassHealth Drug List.